Cardiology Registry to Track Stent Impact

A new database that will include about 15,000 patients at more than 200 U.S. hospitals will track the use of drug-eluting stents and their impact on cardiology patients and procedures.

Called the D.E.S. (drug-eluting stents) cover Registry, the database will capture a wide range of information about current interventional cardiology practices and procedures, including extensive clinical performance and safety findings as well as health, economic, and patient quality-of-life data. Patients will be followed for at least 12 months following treatment. The registry was established by Cordis Cardiology, a division of Cordis Corp. (Miami, FL, USA). The company developed and manufactures the Cypher sirolimus-eluting coronary stent for the treatment of de novo coronary artery lesions. Cordis is working closely with the registry's 13-member scientific advisory committee to identify important variables to measure.

"This landmark study is intended to yield a real-world ‘snapshot' of the impact of drug-eluting stents on today's practice of interventional cardiology,” said principal investigator David O. Williams, M.D., of Brown University (Providence, RI, USA). Dr. Williams explained that the registry will enroll consecutive patients treated with drug-eluting stents, bare metal stents, and balloon angioplasty.




Related Links:
Cordis